Product Details
| Product Name:
LLS30 |
CAS No.:
2138367-58-3 |
| Supply Ability:
10g |
Release date:
2026/06/10 |
Product Introduction
Bioactivity
| Name | LLS30 |
| Description | LLS30 is an allosteric inhibitor of Galectin-1 (Gal-1). LLS30 inhibits the downstream MEK/ERK signaling pathway and also inhibits Akt phosphorylation. LLS30 exhibits potent proliferation-inhibitory activity against various prostate cancer cell lines. |
| In vitro | Methods: NF96.2 and NF02.2 cells were treated with LLS30 at various concentrations (0, 1.5, 3, 10, 20, 50, 100 μM) for 72 hours, and cell viability was assessed using the MTT assay.
Results: LLS30 inhibited proliferation in a dose-dependent manner, with IC?? values of 2.9 μM and 3.6 μM for NF96.2 and NF02.2, respectively. [1]
Methods: NF96.2 and NF02.2 cells were treated with 5 μM LLS30 for 12 and 24 hours, and caspase-3/7 activity was detected.
Results: LLS30 significantly increased caspase-3/7 activity and induced MPNST cell apoptosis in a time-dependent manner. [1]
Methods: PC3, DU145, 22RV1, and CWR-R1 cells were seeded at 3 × 103 cells per well and treated with (1, 5, 10, 25, 50, 100 μM) LLS30 for 72 h; cell viability was assessed using the CellTiter-Glo assay.
Results: LLS30 inhibited CRPC cell proliferation in a dose-dependent manner, with IC?? values of 10.4 μM for PC3, 5.3 μM for DU145, 3.3 μM for 22RV1, and 5.9 μM for CWR-R1.[2] |
| In vivo | Methods: An in situ tumor model was established by injecting NF96.2 cells into the sciatic nerve of nude mice. After tumor formation, LLS30 (10 mg/kg, once daily for 14 consecutive days) was administered intraperitoneally, and tumor burden was monitored using in vivo imaging.
Results: In the LLS30 group, tumor bioluminescence signals were significantly reduced, tumor growth was strongly inhibited, and the formation of lung metastases was almost completely suppressed. [1]
Methods: Nude mice were subcutaneously inoculated with 22RV1 cells. After tumor formation, LLS30 (30 mg/kg, daily for 2 consecutive weeks) was administered intraperitoneally, and tumor volume and body weight were monitored.
Results: LLS30 significantly inhibited tumor growth, reduced the Ki-67 positivity rate by 38.8%, and caused no significant weight loss in mice, demonstrating good safety. [2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | proMMP-9 inhibitor-3c | LLS-30 | LLS30 | LLS 30 |
| Inhibitors Related | G3-C12 acetate(848301-94-0 free base) | N-Acetyl-D-galactosamine | Apoptosis inducer 8 | Thiodigalactoside | 4,5-Dibromo-1H-Pyrrole-2-Carboxylic Acid | N-acetyl-D-Lactosamine | SNAP 398299 | GB1107 | Selvigaltin | OTX008 | Oloctinebart | TD139 |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States